rosiglitazone has been researched along with Arterial Occlusive Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bishop-Bailey, D; Hla, T; Warner, TD | 1 |
Al-Omran, M; Cherng, WJ; Ciliberti, N; Fedak, PW; Li, RK; Li, SH; Stanford, WL; Szmitko, PE; Verma, S; Wang, CH; Weisel, RD | 1 |
2 other study(ies) available for rosiglitazone and Arterial Occlusive Diseases
Article | Year |
---|---|
Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy.
Topics: Animals; Arterial Occlusive Diseases; CD36 Antigens; Cell Line; Cells, Cultured; Cyclooxygenase 2; Drug Delivery Systems; Isoenzymes; Ligands; Male; Muscle, Smooth, Vascular; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Intima; Tunica Media | 2002 |
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
Topics: Angioplasty; Animals; Arterial Occlusive Diseases; Bone Marrow Transplantation; Cell Differentiation; Cell Lineage; Cells, Cultured; Colony-Forming Units Assay; Culture Media, Conditioned; Endothelial Cells; Endothelium, Vascular; Femoral Artery; Humans; Hyperplasia; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Multipotent Stem Cells; Muscle Cells; Muscle, Smooth, Vascular; Neovascularization, Physiologic; Radiation Chimera; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Transcription Factors; Tunica Intima; Vascular Endothelial Growth Factor A | 2004 |